3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Head & Neck
95
Gastrointestinal
6
Thoracic
4
Gynecologic
4
Breast
3
Genitourinary
2
Other
1
Dermatologic
1
CNS
1
Conditions
Urinary Bladder Neoplasms
20
Carcinoma, Renal Cell
12
Colorectal Neoplasms
10
Kidney Neoplasms
8
Ovarian Neoplasms
6
Neoplasms
5
Carcinoma, Transitional Cell
5
Urethral Neoplasms
4
Stomach Neoplasms
4
Prostatic Neoplasms
4
Pancreatic Neoplasms
4
Neoplasm Metastasis
4
Lung Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Breast Neoplasms
4
Triple Negative Breast Neoplasms
3
Melanoma
3
Head and Neck Neoplasms
3
Esophageal Neoplasms
3
Colonic Neoplasms
3
Uterine Cervical Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Rectal Neoplasms
2
Multiple Myeloma
2
Hematologic Neoplasms
2
Fallopian Tube Neoplasms
2
Endometrial Neoplasms
2
Cholangiocarcinoma
2
Carcinoma, Hepatocellular
2
Urothelial Carcinoma of the Bladder
1
Interventions
pembrolizumab
50
Nivolumab
21
Docetaxel
11
atezolizumab
7
Ipilimumab
7
avelumab
6
Cyclophosphamide
6
Paclitaxel
5
Cetuximab
5
Carboplatin
5
fludarabine
4
Radiotherapy
4
Gemcitabine
4
utomilumab
3
spartalizumab
3
lenvatinib
3
durvalumab
3
Trastuzumab
3
Specimen Handling
3
Interleukin-2
3
Cisplatin
3
Bevacizumab
3
Albumin-Bound Paclitaxel
3
zimberelimab
2
tremelimumab
2
tisotumab vedotin
2
tislelizumab
2
sargramostim
2
obinutuzumab
2
epacadostat
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Squamous Cell Carcinoma of Head and Neck
×
Fluorouracil
×
Genitourinary
×
Clear all
NCT05891171
2026-03-31
ARC-25
Arcus Biosciences, Inc.
Phase 1
Active not recruiting
40 enrolled
NCT05007106
2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2
Completed
613 enrolled